A message from BioCryst
Delegates welcomed some new and familiar faces from the pharmaceutical company BioCryst, the Diamond Sponsor of the 2025 HAEi Regional Conference EMEA.
Charlie Gayer, the Chief Commercial Officer for BioCryst, led the 3-strong presentation team. Next to him were Abid Karim, General Manager for Europe, and Sandra Nestler-Parr, the Value and Patient Access Lead, who greeted the audience in a wide range of European languages.
Charlie gave a brief history of BioCryst, sharing that in 2019, the entire company, comprising fewer than 100 people, attended the US HAEA Summit. They were there, he said, to thank the patient community, something that remains at the heart of the organization.
‘We’ve always been so thankful to the HAE patient community, which continues to inspire us.’
The company has grown significantly since 2019 and today has around 500 employees globally, with approximately 100 supporting the HAE community in Europe. That group of people is now transitioning to work as part of a company called Neopharmed Gentili, an Italian pharmaceutical company based in Milan. The team will continue to support the HAE community and aim to help people with other rare diseases across Europe. Charlie confirmed the commitment to HAE remains unchanged.
And, Sandra noted, that commitment begins with market access. Across the EMEA region, their oral HAE treatment is available in 28 countries and counting. This level of access is just the start, with expansion in access the goal of BioCryst and Neopharmed Gentili.
‘Let’s be absolutely clear, without the amazing advocacy efforts of HAEi and its Member Organizations, we would not have been nearly so successful in our efforts.’
The BioCryst team recounted how their CEO, Jon Stonehouse, had made a further commitment: they would bring their drug to countries around the world, regardless of their ability to pay. This promise is now beginning to come true, with pilot programs in place in certain countries, and the 105 HAEi Member Organizations providing a starting map of all the countries where the company hopes to bring its medicine.
The BioCryst delegation left the stage, expressing their gratitude for attending the meeting and thanking the participants for their time.
